ADMA

Adma Biologics (ADMA) outperformed the broader market on October 8, 2026, rising 1.87% to $10.33 while the S&P 500 declined 0.47%. The infectious disease drug developer has gained 7.3% over the past month and is expected to report EPS of $0.19 (up 18.75% YoY) with revenue of $139.8 million (up 4.16% YoY). The company trades at a Forward P/E of 13.06, a discount to its industry average of 23.26, and currently holds a Zacks Rank of #3 (Hold).

ADMA Biologics has attracted investor attention with shares returning +7.3% over the past month, outperforming the S&P 500's +1.4% gain. The company is expected to post earnings of $0.19 per share for the current quarter (+18.8% YoY) and $0.78 for the fiscal year (+30% YoY).

However, with a Zacks Rank #3 (Hold) rating and consensus estimates remaining unchanged over the past month, the stock is expected to perform in line with the broader market in the near term. The company trades at a valuation discount to peers with a B grade on the Value Style Score.